Saniona AB (SANION) - Total Liabilities

Latest as of December 2025: Skr44.58 Million SEK ≈ $4.80 Million USD

Based on the latest financial reports, Saniona AB (SANION) has total liabilities worth Skr44.58 Million SEK (≈ $4.80 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Saniona AB equity growth rate to track the company's year-over-year net asset growth rate.

Saniona AB - Total Liabilities Trend (2012–2025)

This chart illustrates how Saniona AB's total liabilities have evolved over time, based on quarterly financial data. See Saniona AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Saniona AB Competitors by Total Liabilities

The table below lists competitors of Saniona AB ranked by their total liabilities.

Company Country Total Liabilities
Great Rich Technologies Limited
KQ:900290
Korea ₩1.24 Trillion
Pioneer Municipal High Income Trust
NYSE:MHI
USA $59.28 Million
Trivium Real Estate Socimi SA
MC:YTRI
Spain €269.98 Million
Deep Value Driller AS
OL:DVD
Norway Nkr103.56 Million
Churchill Capital Corp X Class A Ordinary Shares
NYSE:CCCX
USA $27.36 Million
Arwana Citramulia Tbk
JK:ARNA
Indonesia Rp931.16 Billion
Skue Sparebank
OL:SKUE
Norway Nkr23.76 Billion
Taiyen Biotech Co Ltd
TW:1737
Taiwan NT$1.39 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Saniona AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Saniona AB.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 13.48 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 13.03 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.07 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Saniona AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Saniona AB (2012–2025)

The table below shows the annual total liabilities of Saniona AB from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr44.58 Million
≈ $4.80 Million
-58.69%
2024-12-31 Skr107.92 Million
≈ $11.61 Million
+25.36%
2023-12-31 Skr86.08 Million
≈ $9.26 Million
-14.76%
2022-12-31 Skr100.99 Million
≈ $10.87 Million
-36.18%
2021-12-31 Skr158.25 Million
≈ $17.03 Million
+78.36%
2020-12-31 Skr88.72 Million
≈ $9.55 Million
+136.20%
2019-12-31 Skr37.56 Million
≈ $4.04 Million
-13.88%
2018-12-31 Skr43.62 Million
≈ $4.69 Million
+305.86%
2017-12-31 Skr10.75 Million
≈ $1.16 Million
-34.93%
2016-12-31 Skr16.52 Million
≈ $1.78 Million
+249.20%
2015-12-31 Skr4.73 Million
≈ $509.02K
-29.19%
2014-12-31 Skr6.68 Million
≈ $718.87K
-53.92%
2013-12-31 Skr14.50 Million
≈ $1.56 Million
+51.63%
2012-12-31 Skr9.56 Million
≈ $1.03 Million
--

About Saniona AB

ST:SANION Sweden Biotechnology
Market Cap
$203.50 Million
Skr1.89 Billion SEK
Market Cap Rank
#16438 Global
#270 in Sweden
Share Price
Skr13.70
Change (1 day)
-3.72%
52-Week Range
Skr8.16 - Skr27.50
All Time High
Skr52.03
About

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more